Veracyte Posts Over 20% Q4 Revenue Increase, Outlines Diagnostics Expansion
Veracyte reported Q4 2025 revenue growth of over 20%, driven by rising volumes of its Afirma thyroid and Percepta lung tests. Management unveiled a strategic plan to invest in its nCounter diagnostics platform and cut operating expenses by roughly 10% in 2026.
1. Q4 Financial Performance
Veracyte delivered Q4 2025 revenue growth exceeding 20% year-over-year, led by increased volumes of its core Afirma thyroid and Percepta lung cancer tests. The company cited improved reimbursement rates and higher test adoption across U.S. clinics as key drivers of the top-line gain.
2. Strategic Initiatives and Outlook
Management announced a plan to invest in expanding its nCounter diagnostics platform, allocating capital to accelerate R&D and commercial rollout. Simultaneously, the company will reduce operating expenses by about 10% through headcount optimization and streamlined G&A to bolster profitability in 2026.